Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010 (2010), Article ID 761571, 7 pages
http://dx.doi.org/10.4061/2010/761571
Research Article

Combined Analysis of CSF Tau, A 42, A 1–42% and A 1– % in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

1Department of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Henricistrasse 92, 45136 Essen, Germany
2Department of Psychiatry, Psychotherapy, Rheinische Kliniken Essen, University of Duisburg-Essen, 45147 Essen, Germany
3Department of Psychiatry and Psychotherapy, University of Erlangen, Schwabachanlage 6, 91054 Erlangen, Germany
4Paracelsus-Elena Klinik, University of Goettingen, 34128 Kassel, Germany
5Institute for Neurology, University of Ulm, 89075 Ulm, Germany

Received 15 April 2010; Revised 8 July 2010; Accepted 11 July 2010

Academic Editor: Lucilla Parnetti

Copyright © 2010 Mirko Bibl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We studied the diagnostic value of CSF A 42/tau versus low A 1–42% and high A 1– % levels for differential diagnosis of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), respectively. CSF of 45 patients with AD, 15 with DLB, 21 with Parkinson's disease dementia (PDD), and 40 nondemented disease controls (NDC) was analyzed by A -SDS-PAGE/immunoblot and ELISAs (A 42 and tau). A 42/tau lacked specificity in discriminating AD from DLB and PDD. Best discriminating biomarkers were A 1–42% and A 1– % for AD and DLB, respectively. AD and DLB could be differentiated by both A 1–42% and A 1– % with an accuracy of 80% at minimum. Thus, we consider A 1–42% and A 1– % to be useful biomarkers for AD and DLB, respectively. We propose further studies on the integration of A 1–42% and A 1– % into conventional assay formats. Moreover, future studies should investigate the combination of A 1– % and CSF alpha-synuclein for the diagnosis of DLB.